Download this article

Oxular Appoints David Fellows
as Chairman of the Board

• David Fellows appointed as Chairman of Oxular’s Board of Directors
• David has more than 30 years of experience in various leadership roles within the ophthalmic
pharmaceutical industry

10 January 2017 – Oxular Limited, the Oxford-based retinal therapeutics company, today announces
the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of
the Board. Mr. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a
Director.
David Fellows brings a wealth of ophthalmology and organisational leadership experience to Oxular.
He is currently Chief Executive Officer of NightstaRx Limited, a private biopharmaceutical company
specialising in developing ocular gene therapies for patients with inherited retinal dystrophies. He
was previously Vice President of Johnson & Johnson’s Vision Care Franchise where he led global
marketing, new product and licensing activities. Prior to that he was employed at Allergan for 25
years where he served in a number of sales and marketing roles, including Regional President,
Corporate Vice President and Senior Vice President in locations in North America, Europe and Asia.
Tom Cavanagh, Chief Executive Officer of Oxular Limited, commented:
“We welcome David as Chairman of our board. We believe that with his expertise in the ophthalmic
industry David will play a key role in helping us to achieve our goal of building a global ophthalmic
franchise developing innovative treatments for retinal diseases. I would also like to take this
opportunity to thank Nigel Pitchford for his invaluable leadership during Oxular’s first year of
operations and am pleased that we will continue to benefit from his experience as a Board Director.”
David Fellows, Chairman of the Board of Oxular Limited, commented:
“I am delighted to be appointed Chairman at this exciting time in the Company’s development. Oxular
is committed to utilising its expertise to develop and register novel therapies for treating patients with
sight-threatening retinal diseases. We have a talented team and I look forward to working with them
as we advance our product portfolio.”
Enquiries
FTI Consulting Tel: +44 (0)20 3727 1000
Ben Atwell / Mo Noonan
About Oxular Limited
Founded in 2014, Oxular is developing novel retinal treatments engineered to access specific small
spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal
diseases. The unique approach aims to increase therapeutic effectiveness, reduce side-effects and
minimise frequency of treatments. Oxular’s product development pipeline includes treatments for both
prevalent retinal diseases, such as age related macular degeneration and diabetic macular oedema,
as well as rare and orphan indications (www.oxular.com).